**NM signifies a non meaningful value. A dash signifies the data is not available.
Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result ...
Hosted on MSN
Healthy Returns: Novo Nordisk’s head of research and development previews the first-ever obesity pill
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. We're inching ...
Novo Nordisk CEO: Confident from supply perspective on the Wegovy pill Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results